At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 190 enrolled
Drug / intervention
SHR 1210+apatinibdrug
Likely dose
SHR 1210+apatinib 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-arm, Open-label Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC
In Brief
A Phase 2 clinical trial evaluating SHR 1210+apatinib for Hepatocellular Carcinoma. Completed, enrolled 190 participants across 1 site.
Detailed Summary
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedMar 2018
Primary CompletionMar 2021
TodayJul 2026
First PostedMar 13, 2018
Enrollment StartMar 8, 2018
Primary CompletionMar 10, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.3 years ago
Interventions
SHR 1210+apatinibdrug
SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.